Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

SAN FRANCISCO — Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic ...

New data from 33 abstracts, including one oral presentation and four late-breaking posters will be presented at the American Thoracic Society (ATS) International Conference in San Francisco, ...

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma ...

Asthma data reinforce impact of Dupixent on mucus burden, exacerbations and disease control A late-breaking poster on the VESTIGE imaging trial will highlight that Dupixent reduced mucus burden, ...

For example, dupilumab is optimal for treating concomitant asthma and other forms of atopy, whereas nemolizumab — coupled with a topical steroid — may be appropriate for patients with severe itch, ...

"This may suggest that the window of opportunity for catch-up growth may be primarily in the <12 years age group," her group reported in the poster presentation.

Given that dupilumab is already FDA-approved for asthma and eczema, there is potential for swift clinical testing alongside immunotherapy to enhance survival in ovarian cancer patients.